GlobeNewswire: Excision BioTherapeutics Contains the last 10 of 30 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:49:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/10/25/2766525/0/en/Excision-BioTherapeutics-Presents-Positive-Interim-Clinical-Data-from-Ongoing-Phase-1-2-Trial-of-EBT-101-for-the-Treatment-of-HIV-at-ESGCT-30th-Annual-Congress.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress2023-10-25T12:30:00Z<![CDATA[SAN FRANCISCO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced positive safety data from the first dose cohort in its first-in-human Phase 1/2 trial to assess safety and pharmacodynamics of EBT-101. EBT-101 is a dual-guide, CRISPR-based investigational gene therapy for the treatment of human immunodeficiency virus type 1 (HIV-1). The data was presented at the European Society for Gene & Cell Therapy annual meeting on October 25, 2023 in Brussels, Belgium.]]>https://www.globenewswire.com/news-release/2023/10/19/2763098/0/en/Excision-BioTherapeutics-Announces-Presentation-of-Interim-Clinical-Data-for-EBT-101-in-Latent-HIV-at-Upcoming-European-Society-of-Gene-and-Cell-Therapy-ESGCT-2023-Annual-Congress.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress2023-10-19T11:50:46Z<![CDATA[SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.]]>https://www.globenewswire.com/news-release/2023/08/17/2727153/0/en/Excision-BioTherapeutics-Announces-Gene-Therapy-Publication-of-Pre-Clinical-Data-Supporting-its-First-in-Class-CRISPR-Based-Gene-Therapy-Candidate-Designed-to-Functionally-Cure-HIV.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-12023-08-17T11:30:00Z<![CDATA[SAN FRANCISCO, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced the publication of data in the journal Gene Therapy showing that EBT-001 – a simian-specific analogue of EBT-101 – safely removes the simian form of HIV from the genomes of non-human primates. The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.]]>https://www.globenewswire.com/news-release/2023/07/20/2708048/0/en/Excision-BioTherapeutics-Receives-FDA-Fast-Track-Designation-for-EBT-101-a-First-in-Class-CRISPR-Based-Gene-Therapy-Candidate-to-Functionally-Cure-HIV-1.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-12023-07-20T11:00:00Z<![CDATA[SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its CRISPR-based therapy, EBT-101, a dual-cut CRISPR-based gene therapy for the treatment of human immunodeficiency virus type 1 (HIV-1). EBT-101 is being tested in an ongoing Phase 1/2 trial to assess its safety and tolerability in adults (18 to 65 years old) with HIV-1 who are on continuous antiretroviral therapy with HIV RNA below the level of detection.]]>https://www.globenewswire.com/news-release/2023/06/01/2680384/0/en/Excision-BioTherapeutics-Appoints-Former-Pfizer-Chairman-and-CEO-Jeffrey-B-Kindler-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors2023-06-01T13:00:00Z<![CDATA[SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases, today announced the appointment of Jeffrey B. Kindler, former Chairman and Chief Executive Officer (CEO) of Pfizer and current CEO of Centrexion Therapeutics, to its Board of Directors. The appointment expands his role on Excision’s Business Advisory Board.]]>https://www.globenewswire.com/news-release/2022/10/20/2538290/0/en/Excision-BioTherapeutics-to-Host-Key-Opinion-Leader-Webinar-on-HIV-and-the-Ongoing-Phase-1-2-Trial-Evaluating-EBT-101-as-a-Potential-Cure.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure 2022-10-20T12:00:00Z<![CDATA[Webinar will focus on the unmet medical need in HIV, therapeutic applications of gene delivery and editing for treatment of viral disease, and the Company’s ongoing Phase 1/2 trial evaluating the CRISPR-based therapy, EBT-101, as a treatment for HIV]]>https://www.globenewswire.com/news-release/2022/09/29/2525066/0/en/Excision-BioTherapeutics-Awarded-California-Institute-for-Regenerative-Medicine-CIRM-Grant-to-Support-Ongoing-Phase-1-2-Trial-Evaluating-EBT-101-as-a-Potential-Cure-for-HIV.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV2022-09-29T11:30:00Z<![CDATA[SAN FRANCISCO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Excision a $6.85 million grant to support the clinical development of the EBT-101 program for human immunodeficiency virus type 1 (HIV-1).]]>https://www.globenewswire.com/news-release/2022/09/15/2516733/0/en/Excision-BioTherapeutics-Doses-First-Participant-in-EBT-101-Phase-1-2-Trial-Evaluating-EBT-101-as-a-Potential-Cure-for-HIV.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV2022-09-15T11:00:00Z<![CDATA[SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1). The participant was dosed in July 2022, with initial findings indicating EBT-101 has been well tolerated to-date. The participant continues to be monitored for safety and is expected to qualify for analytical treatment interruption (ATI) of their background anti-retroviral therapy (ART) in an evaluation of a potential cure.]]>https://www.globenewswire.com/news-release/2022/09/09/2513209/0/en/Excision-BioTherapeutics-to-Present-at-Upcoming-Conferences.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics to Present at Upcoming Conferences2022-09-09T11:30:00Z<![CDATA[SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that Excision Management will present at the following upcoming investor conferences.]]>https://www.globenewswire.com/news-release/2022/06/07/2458212/0/en/Excision-BioTherapeutics-to-Participate-in-the-Jefferies-Healthcare-Conference-on-Thursday-June-9-2022-at-2-00-p-m-ET.html?f=22&fvtc=4&fvtv=55584Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET2022-06-07T20:05:00Z<![CDATA[SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. Eastern Time in New York City, NY.]]>